Immune Targeting Systems (ITS) Ltd.

https://www.its-innovation.com

Immune Targeting Systems focused on the development of T-cell vaccines to highly mutated viruses and to cancers utilizing its proprietary long-peptide based Depovaccine® platform. The company is supported by Novartis Venture Fund, HealthCap, Truffle Capital, Esperante Ventures and London SME. *

	Start	2013-10-10 existent
	Group	Altimmune (Group)
	Today	Altimmune (Group)
	Successor	Altimmune (Group)
	Industry	BIOTECH
	Industry 2	vaccine, hepatitis B
	Person	Chen, Benjamin (Immune Targeting Systems Ltd 201501 CEO)

	Street	2 Royal College Street London Bioscience Innovation Centre
	City	NW1 0NH London
	Tel	+44-20-7691-4908
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture Berlin Partner Top News New Ariceum Radiopharma Lab 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)